IRVINE, Calif., Sept. 8 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, today announced that the Fire Department of New York City (FDNY) has purchased 86 Masimo Rad-57 Pulse CO-Oximeters as part of their strategic initiative to "improve the survivability of firefighters and victims suffering from carbon monoxide (CO) toxicity." The purchase is the single largest first responder deployment of Rad-57s, making FDNY the largest department to implement a department-wide program for noninvasive carbon monoxide monitoring in the U.S.
The Masimo Rad-57 Pulse CO-Oximeter enables EMS and fire department first responders to quickly, accurately, and noninvasively detect carbon monoxide poisoning on the scene. FDNY will put its 86 new Rad-57s to work throughout the 5 boroughs of New York City on all 35 of its HazTac and rescue ambulances, Supervisor units, and Major Emergency Response Vehicles -- allowing for prompt and possibly life-saving treatment for both victims and firefighters alike.
According to John Peruggia, Chief of EMS for the Fire Department City of New York, the Masimo Rad-57 Pulse CO-Oximeter has become a key component in FDNY fire and emergency medical response operations "because it allows our EMTs and Paramedics to accurately evaluate a patient's blood chemistry, determine toxicity levels, and commence initial treatment of patients found to be poisoned by CO -- all within seconds. The Rad-57 has also become an integral part of firefighter rehab, with all fire personnel being evaluated for CO after operating at large fire incidents, to insure responder health and safety. Expanding our utilization of the Rad-57 with this purchase is a natural progression of the success we have achieved, both in terms of lives saved and hazards averted."
Masimo Founder and CEO, Joe E. Kiani, stated, "We commend FDNY for their leadership, dedication, and vigilance in the battle against the unsuspected, deadly hazards of carbon monoxide poisoning. We are particularly proud that they have chosen the Rad-57 to help ensure the public health and safety of all New York City residents, visitors, and first responders."
The Fire Department City of New York (FDNY) is the largest combined Fire and EMS provider in the United States. With more than 11,000 firefighters and 3,000 EMTs and paramedics, FDNY provides the fire protection and inspection, emergency medical, technical rescue, and biological, chemical and radioactive hazard first response services for more than 8 million citizens in an area of more than 320 square miles. Annually, FDNY responds to over 990,000 fire calls, more than 1.3 million EMS calls.
Masimo (Nasdaq: MASI) develops innovative monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low-Perfusion pulse oximetry, known as Masimo SET((R)), which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET((R)) Pulse CO-Oximetry(TM), a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO((R))), methemoglobin (SpMet((R))), and PVI(TM), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our belief that Masimo Rad-57 will provide sufficient sensitivity and specificity to detect elevated levels of carboxyhemoglobin and potentially life-threatening carbon monoxide poisoning within seconds for all patients and will provide an effective early warning system to enable timely rescue, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Media Contacts: Dana Banks Masimo Corporation +1 (949) 297-7348
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57, Rad-9, Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.
|SOURCE Masimo Corporation|
Copyright©2009 PR Newswire.
All rights reserved